Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 3

1(33.3%)

3Total

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05000242Active Not Recruiting

West Hertfordshire Inflammatory Bowel Disease Technology Study

Role: collaborator

NCT03994653Completed

Cancer Loyalty Card Study

Role: collaborator

NCT05365828Active Not Recruiting

Legacies and Futures: Measuring Roles of Resilience and Vulnerability in Pregnancy and Birth Outcomes

Role: collaborator

NCT03653832Phase 3Completed

Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

Role: collaborator

NCT05308550Not ApplicableCompleted

Clinical Evaluation of Rapid RNA Test for Covid-19

Role: collaborator

NCT05298462Not ApplicableCompleted

Clinical Evaluation of Rapid Antibody Test for Covid-19

Role: collaborator

NCT01507415Completed

Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?

Role: collaborator

All 7 trials loaded